BASFY and ADAMA Partner to Advance Gilboa Fungicide in Europe

BASF SE’s BASFY Agricultural Solutions unit and ADAMA Ltd. have entered into a strategic co-development and commercialization deal focused on ADAMA’s proprietary fungicide active ingredient, Gilboa (flumetylsulforim). The collaboration will accelerate the delivery of novel and advanced disease management solutions. The partnership will aim to benefit European farmers facing resistance challenges and maintain healthy yields.

Under the deal, BASF will develop and commercialize new formulations based on the Gilboa molecule, alongside ADAMA’s Gilboa-based products. The collaboration will build on ADAMA’s innovation alongwith BASF’s development expertise and strong access across Europe. Both companies will independently determine their own product concepts, pricing, sales and go-to-market strategies.

Gilboa offers a novel mode of action for cereals and is classified under the Fungicide Resistance Action Committee (FRAC) Group 32, targeting nucleic acid metabolism. The molecule provides a new solution in Europe to the challenges of high regulatory pressure and the phase-out of existing active ingredients. It is expected to support yield and quality while offering long-lasting disease control solutions.

Both companies share a commitment to innovation, sustainability and delivering quality to farmers. This collaboration will speed up access to cutting-edge fungicide technologies. Subject to approval, Gilboa-based formulations for wheat are expected to be launched by both companies in Great Britain in 2027, with wider European launches planned for 2029.

BASFY’s shares have gained 20.4% over the past year compared with the industry’s 13.9% decline.

BASFY’s Zacks Rank & Key Picks

BASFY currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the Basic Materials space are Kinross Gold Corporation KGC, Fortuna Mining Corp. FSM and Equinox Gold Corp. EQX.

At present, KGC sports a Zacks Rank #1 (Strong Buy), while FSM and EQX carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for KGC’s current-year earnings is pegged at $1.67 per share, indicating a rise of 145.59%. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing once, with an average surprise of 17.37%. KGC’s shares have gained 208.7% over the past year.

The Zacks Consensus Estimate for FSM’s current fiscal-year earnings is pinned at 76 cents per share, indicating a 65.22% year-over-year increase. Its shares have surged 126.4% over the past year.

The Zacks Consensus Estimate for EQX’s current-year earnings stands at 54 cents per share, implying a 170% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, with the average earnings surprise of 87%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research